Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-05-10
2011-05-10
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S249000, C514S253040, C514S274000, C514S300000, C514S301000, C544S127000, C544S318000, C544S350000, C544S362000, C546S114000, C546S122000
Reexamination Certificate
active
07939527
ABSTRACT:
Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.
REFERENCES:
patent: 4273778 (1981-06-01), Hadley
patent: 4321378 (1982-03-01), Dostert
patent: 4329466 (1982-05-01), Dostert
patent: 4336259 (1982-06-01), Hadley
patent: 4352802 (1982-10-01), Blaney
patent: 4410535 (1983-10-01), Watts
patent: 4424358 (1984-01-01), Dostert
patent: 4432983 (1984-02-01), Riley
patent: 4471120 (1984-09-01), Dostert
patent: 4536580 (1985-08-01), Dostert
patent: 4544660 (1985-10-01), Hadley
patent: 4599420 (1986-07-01), Hadley
patent: 4705858 (1987-11-01), Hadley
patent: 5585492 (1996-12-01), Chandrakumar et al.
patent: 5700816 (1997-12-01), Isakson et al.
patent: 5719306 (1998-02-01), Chandrakumar et al.
patent: 5723492 (1998-03-01), Chandrakumar et al.
patent: 5990148 (1999-11-01), Isakson
patent: 6110944 (2000-08-01), Chen et al.
patent: 6316490 (2001-11-01), Vernier
patent: 6407140 (2002-06-01), Gregory et al.
patent: 6432976 (2002-08-01), Thompson
patent: 6506876 (2003-01-01), Chandrakumar et al.
patent: 6559140 (2003-05-01), Bennani et al.
patent: 6632823 (2003-10-01), Vernier
patent: 2003/0004191 (2003-01-01), Gregory et al.
patent: 2005/0043355 (2005-02-01), Gregory et al.
patent: 2005/0043378 (2005-02-01), Bembenek et al.
patent: 2005/0043379 (2005-02-01), Bembenek et al.
patent: 2006/0074121 (2006-04-01), Chen et al.
patent: 2006/0223792 (2006-10-01), Butler et al.
patent: 2007/0079078 (2007-04-01), Fujita et al.
patent: 2007/0155726 (2007-07-01), Arnaiz et al.
patent: 2007/0167425 (2007-07-01), Nakade et al.
patent: 2008/0057074 (2008-03-01), Takaoka
patent: 2008/0194630 (2008-08-01), Barchuk et al.
patent: 2009/0111794 (2009-04-01), Bacani et al.
patent: 0266576 (1988-05-01), None
patent: 416521 (1990-09-01), None
patent: 623621 (1994-04-01), None
patent: 2446823 (1979-01-01), None
patent: 63170356 (1988-07-01), None
patent: WO 96/11192 (1996-04-01), None
patent: WO 96/41625 (1996-12-01), None
patent: WO 97/29774 (1997-08-01), None
patent: WO 01/81347 (2001-01-01), None
patent: WO 03/037904 (2003-05-01), None
patent: WO 2004/103959 (2004-12-01), None
patent: WO 2006/002133 (2006-01-01), None
patent: WO 2006/004475 (2006-01-01), None
patent: WO 2006/133802 (2006-12-01), None
patent: WO 2007/007069 (2007-01-01), None
patent: WO 2007/079078 (2007-07-01), None
patent: WO 2008/016811 (2008-02-01), None
Alestas, T. et al. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J. Mol. Med. 2006, 84(1), 75-87.
Andoh, T. et al. Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in mice. Eur. J. Pharmacol. 1998, 353(1), 93-96.
Andoh, T. et al. Involvement of blockade of leukotriene B4 action in anti-pruritic effects of emedastine in mice. Eur. J. Pharmacol. 2000, 406(1), 149-152.
Andoh, T. et al. Involvement of leukotriene B4 in substance P-induced itch-associated response in mice. J. Investigativ. Dermatol. 2001, 117(6), 1621-1626.
Andoh, T. et al. Intradermal nociceptin elicits itch-associated responses through leukotriene B4 in mice. J. Investigativ. Dermatol. 2004, 123(1), 196-201.
Andoh, T. et al. Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice. Eur. J. Pharmacol. 2006, 547(1-3), 59-64.
Barnes, P.J. Future Advances in COPD Therapy. Respiration 2001, 68(5), 441-448.
Bagshawe et al. Antibody-Directed Enzyme Prodrug Therapy: A Review Drug Dev. Res. 1995, 34, 220-230.
Barone, F.C. et al. Time-related changes in myeloperoxidase activity and leukotriene B4 receptor binding reflect leukocyte influx in cerebral focal stroke. Mol. Chem. Neuropathol. 1995, 24(1), 13-30.
Benoist, C. and D. Mathis. Mast Cells in Autoimmune Disease. Nature 2002, 420(6917), 875-878.
Berge et al. Pharmaceutical Salts Journal of Pharmaceutical Sciences 1977, 66(1), 1-19.
Bertolini et al. A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, A Potent Immunosuppressive Drug. J Med Chem 1997, 40, 2011-2016.
Bodor et al. Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems Advances in Drug Research 1984, 13, 224-331.
Byrum, R.S. et al. Determination of the Contribution of Cysteinyl Leukotrienes and Leukotriene B4in Acute Inflammatory Responses Using 5-Lipoxygenase- and Leukotriene A4Hydrolase-Deficient Mice. J. Immunol. 1999, 163(12), 6810-6819.
Camp, R.D.R. et al. Responses of Human Skin to Intradermal Injection of Leukotrienes C4, D4and B4. Br. J. Pharmacol. 1983, 80(3), 497-502.
Camp, R. et al. Production of Intraepidermal Microabscesses by Topical Application of Leukotriene B4. J. Invest. Dermatol. 1984, 82(2), 202-204.
Carpagnano, G.E. et al. Increased leukotrien B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003, 167(8), 1109-1112.
Chen, X. et al. Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of bestatin. J. Natl. Cancer Inst. 2003, 95(14), 1053-1061.
Chen, X. et al. Leukotriene A4 hydrolase as a target for cancer prevention and therapy. Curr. Cancer Drug Targets 2004, 4(3), 267-283.
Cohen, J. The Immunopathogenesis of Sepsis. Nature (London) 2002, 420(6917), 885-891.
Coussens, L.M. et al. Inflammation and Cancer. Nature (London) 2002, 420(6917), 860-867.
Crooks, S.W. and R.A. Stockley. Leukotriene B4. Int. J. Biochem. Cell Biol. 1998, 30(2), 173-178.
Cunha, J.M. et al. The critical role of leukotriene B4 in antigen-induced mechanical hyperalgesia in immunised rats. Br. J. Pharmacol. 2003, 139(6), 1135-1145.
Ellis, C.N. et al. Cost of atopic dermatitis and eczema in the United States. J. Am. Acad. Dermatol. 2002, 46, 361-370.
Emingil, G. et al. Levels of leukotriene B4 in gingival crevicular fluid and gingival tissue in specific periodontal diseases. J. Periodontol. 2001, 72(8), 1025-1031.
Fitzpatrick, F.A. et al. Effects of Leukotriene A4on Neutrophil Activation. Ann. N. Y. Acad. Sci. 1994, 714, 64-74.
Ford-Hutchinson, A.W. et al. 5-Lipoxygenase. Ann. Rev. Biochem.1994, 63, 383-417.
Fleisher, D. et al. Improved oral drug delivery: solubility limitations overcome by the use of prodrugs. Advanced Drug Delivery Reviews, 1996, 19, 115-130.
Friedrich E.B. et al. Mechanisms of leukotriene B4-triggered monocyte adhesion. Arterioscler Thromb Vasc Biol 2003, 23, 1761-1767.
Funk et al. Molecular Cloning and Amino Acid Sequence of Leukotriene A4 Hydrolase. PNAS 1987, 84, 6677-6681.
Gelfand, E.W. et al. CD8+ T lymphocytes and leukotriene B4: novel interactions in the persistence and progression of asthma. J. Allergy Clin. Immunol. 2006, 117(3), 577-582.
Gierse et al. High level Experssion and Purification of Human Leukotriene A4 Hydrolase from Insect Cells Infected with a Baculovirus Vector. Protein Expression and Purification, 1993, 4, 358-366.
Gompertz, S. et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur. Respir. J. 2001, 17(6), 1112-1119.
Goodarzi, K. et al. Leukotriene B4and BLT1 Control Cytotoxic Effector T Cell Recruitment to Inflamed Tissues. Nat. Immunol. 2003) 4(10), 965-973.
Griffiths, R.J. et al. Leukotriene B4Plays a Critical Role in the Progression of Collagen-Induced Arthritis. PNAS 1995, 92(2), 517-521.
Hakonarson, H. et al. Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction. A randomized trial. JAMA 2005, 293(18), 2245-2256.
Hanifin, J.M. et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association Administrative Regulations for Evidence-Based Clinical Practice Guidelines. J. Am. Acad. Dermatol. 2004, 50, 391-404.
Helgadottir, A. et al. The Gene E
Bacani Genesis M.
Broggini Diego
Cheung Eugene Y.
Chrovian Christa C.
Deng Xiaohu
Chu Yong
Janssen Pharmaceutica NV
Otton Alicia L
LandOfFree
Thiazolopyridin-2-yloxy-phenyl and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiazolopyridin-2-yloxy-phenyl and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazolopyridin-2-yloxy-phenyl and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2682485